
    
      The study will evaluate the antidepressant effect of one or two administrations of two doses
      of CERC-301 (12 mg and 20 mg) in subjects with MDD who are currently experiencing a severe
      depressive episode despite stable ongoing treatment with a selective serotonin- or
      serotonin-norepinephrine reuptake inhibitor (SSRI or SNRI).
    
  